3-溴-1-甲氧基-2,4-二甲基苯 | 23453-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-溴-1-甲氧基-2,4-二甲基苯
• 英文名称: 2,4-dimethyl-3-bromoanisole
• 英文别名: 2-Brom-4-methoxy-m-xylol；2-Bromo-4-methoxy-1,3-dimethylbenzene；3-bromo-1-methoxy-2,4-dimethylbenzene
• CAS: 23453-90-9
• 化学式: C₉H₁₁BrO
• 分子量: 215.09
• InChiKey: FADYDSCBJSKXOO-UHFFFAOYSA-N

物化性质

• 沸点：
  240.0±35.0 °C(Predicted)
• 密度：
  1.326±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-溴-1-甲氧基-2,4-二甲基苯 在 potassium permanganate 、 碘苯 、 铜 作用下， 生成 4-甲氧基间苯二甲酸二甲酯
  参考文献：
  名称：

  Kobayashi,S. et al., Chemical and pharmaceutical bulletin, 1969, vol. 17, p. 1279 - 1283

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-二甲基硝基苯 在 ferric(III) bromide 、 亚硝酸特丁酯 、 溴 、 铁粉 、 氯化铵 、 copper(I) bromide 、 锌 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 38.0h， 生成 3-溴-1-甲氧基-2,4-二甲基苯
  参考文献：
  名称：

  [EN] INHIBITING HUMAN INTEGRIN α4β7
  [FR] INHIBITION DE L'INTÉGRINE HUMAINE α4β7

  摘要：

  公开号：

  WO2021076890A4

文献信息

• Stabilisation of 2,6‐Diarylpyridinium Cation by Through‐Space Polar–π Interactions
  作者：Joan Simó Padial、René de Gelder、Célia Fonseca Guerra、F. Matthias Bickelhaupt、Jasmin Mecinović

  DOI：10.1002/chem.201304462

  日期：2014.5.19

  The through‐space polar–π interactions between pyridinium ion and the adjacent aromatic rings in 2,6‐diarylpyridines affect the pKa values. Hammett analysis illustrates that the basicity of pyridines correlates well with the sigma values of the substituents at the para position of the flanking aryl rings.

  吡啶鎓离子与2,6-二芳基吡啶中的相邻芳环之间的全空间极性-π相互作用会影响p K a 值。Hammett分析表明，吡啶的碱性与 芳基侧翼对位的取代基的sigma值具有很好的相关性。
• [EN] 1-ARYL-4-SUBSTITUTED ISOQUINOLINES<br/>[FR] ISOQUINOLINES 1-ARYL-4-SUBSTITUEES
  申请人：NEUROGEN CORP

  公开号：WO2005110991A1

  公开（公告）日：2005-11-24

  1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.

  提供了Formula (I)和Formula (II)的1-芳基-4-取代异喹啉类似物，具体如下：其中R1、R2、R3、R8、R9、A和Ar在此处定义。这些化合物是C5a受体的配体。Formula (I)和(II)的优选化合物与C5a受体结合亲和力高，并在C5a受体上表现为中性拮抗剂或逆向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的1-芳基-4-取代异喹啉，可用作C5a受体的定位探针。
• Synthesis of (±)-14-<i>epi</i>-hydroxydolasta-1(15),7,9-triene and (±)-7-<i>epi</i>-acetoxy-14-<i>epi</i>-hydroxydolasta-1(15),8-diene^*Taken in part from the Ph.D. dissertation of Jianhua Yu, University of Georgia, Athens, Georgia, USA, 2009.
  作者：George Majetich、Jianhua Yu

  DOI：10.1139/v11-116

  日期：2012.1

  1,3-Dimethyl-2-nitrobenzene was converted to the key intramolecular Friedel–Crafts intermediate 24 in ten steps. Treatment of 24 with TiCl₄ produced tricyclic enone 25 in 61%–75% yield, having the requisite trans relationship of the two angular methyl groups and many of the salient features of the dolastane diterpenes. The structure of enone 25 was verified by X-ray crystallography analysis. Cyclization product 25 permitted the facile synthesis of (±)-14-epi-hydroxydolasta-1(15),7,9-triene and (±)-7-epi-acetoxy-14-epi-hydroxydolasta-1(15),8-diene, which are detailed in this article.

  1,3-二甲基-2-硝基苯被转化为关键的分子内Friedel-Crafts中间体24，经过十个步骤。用TiCl₄处理24产生三环烯酮25，收率为61%–75%，具有两个角甲基的必需的反式关系和多个dolastane二萜的显著特征。通过X射线晶体学分析验证了烯酮25的结构。环化产物25促进了(±)-14-epi-hydroxydolasta-1(15),7,9-三烯和(±)-7-epi-acetoxy-14-epi-hydroxydolasta-1(15),8-二烯的简便合成，这些在本文中有详细描述。
• 4,5-Disubstituted-2-aryl pyrimidines
  申请人：Maynard D. George

  公开号：US20050277654A1

  公开（公告）日：2005-12-15

  4,5-disubstituted-2-arylpyrimidines of Formula I and Formula II are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.

  提供公式I和公式II的4,5-二取代-2-芳基嘧啶，其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。公式I和II的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含此类化合物的制药组合物，以及使用此类化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的4,5-二取代-2-芳基嘧啶，用于定位C5a受体。
• 3-substituted-6-aryl pyridines
  申请人：Neurogen Corporation

  公开号：US20040158067A1

  公开（公告）日：2004-08-12

  3-substituted-6-aryl pyridines of Formula I are provided: 1 wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptor. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物： 其中，R1、R2、R3、R8、R9、A和Ar的定义如下。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂的活性。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明还提供了标记的3-取代-6-芳基吡啶化合物，可用作C5a受体定位的探针。